title: Efficacy of vaccination of calves against hemorrhagic septicemia with a live aroA derivative of Pasteurella multocida B:2 by two different routes of administration.
abstract: Two groups of four calves each were immunized either intramuscularly (i.m. vaccinated) or intranasally (i.n. vaccinated) at 2 and 6 weeks of age with ca. 10(9) CFU of a derivative of P. multocida serotype B:2 strain 85020 containing a deletion in the aroA gene (strain JRMT12). Both groups of calves and three unvaccinated control calves were challenged subcutaneously at 8 weeks of age with ca. 10(7) CFU of the wild-type 85020 strain. The first and second vaccinations caused a significant pyrexia and increase in the mean demeanor score (P <0.05) in i.m. but not i.n. vaccinated calves. Serum agglutinating activity against whole cells of P. multocida strain 85020 and immunoglobulin G antibody concentrations increased after the second vaccination in i.m. but not in i.n. vaccinated animals, and this difference was statistically significant (P <0.05). Concentrations of serum amyloid A (SAA) increased significantly 3 h after both the primary (P <0.05) and booster (P <0.001) i.m. vaccinations, but not in i.n. vaccinated calves. All four i.m. vaccinated calves were solidly immune to challenge with wild-type P. multocida B:2. However, the mean rectal temperatures, demeanor scores, and serum SAA concentrations of i.n. vaccinated and control calves increased significantly (P <0.01). Three i.n. vaccinated and two control calves were killed for humane reasons within 14 h postchallenge, and postmortem examination revealed pathological lesions consistent with hemorrhagic septicemia. These data showed that the aroA mutant strain, given i.m. as two doses 4 weeks apart, acted as an effective live-attenuated vaccine strain to protect calves against challenge with the virulent parent strain.
authors.affiliation: Infection and Immunity Division, Institute of Biomedical and Life Sciences, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, United Kingdom.
authors.forename: J Christopher
authors.initials: JC
authors.lastname: Hodgson
authors.forename: Anna
authors.initials: A
authors.lastname: Finucane
authors.forename: Mark P
authors.initials: MP
authors.lastname: Dagleish
authors.forename: Saeed
authors.initials: S
authors.lastname: Ataei
authors.forename: Roger
authors.initials: R
authors.lastname: Parton
authors.forename: John G
authors.initials: JG
authors.lastname: Coote
mesh_terms: D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase; D000281:Administration, Intranasal; D019883:Alkyl and Aryl Transferases / Q000235:genetics* / Q000276:immunology; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002417:Cattle; D002418:Cattle Diseases / Q000401:mortality / Q000517:prevention & control*; D006483:Hemorrhagic Septicemia / Q000401:mortality / Q000517:prevention & control / Q000662:veterinary*; D007115:Immunization Schedule; D007273:Injections, Intramuscular; D010326:Pasteurella Infections / Q000401:mortality / Q000517:prevention & control / Q000662:veterinary*; D016979:Pasteurella multocida / Q000145:classification / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D012703:Serotyping; D000685:Serum Amyloid A Protein / Q000032:analysis; D016896:Treatment Outcome; D014611:Vaccination / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D000685:Serum Amyloid A Protein; D014613:Vaccines, Attenuated; D019883:Alkyl and Aryl Transferases; D051229:3-Phosphoshikimate 1-Carboxyvinyltransferase
references.citation: Infect Immun. 2002 Jul;70(7):3355-62
references.pmid: 12065473
references.citation: J Clin Microbiol. 1998 Apr;36(4):1096-100
references.pmid: 9542944
references.citation: Vet Rec. 1998 Apr 18;142(16):428-31
references.pmid: 9595632
references.citation: Vaccine. 1998 Jul;16(11-12):1184-92
references.pmid: 9682378
references.citation: Vet Microbiol. 1999 Mar 12;65(3):233-40
references.pmid: 10189198
references.citation: Vet Rec. 1999 Apr 17;144(16):437-41
references.pmid: 10343375
references.citation: Vaccine. 2000 Nov 22;19(7-8):751-7
references.pmid: 11115696
references.citation: Microb Pathog. 2001 Mar;30(3):171-8
references.pmid: 11273743
references.citation: Res Vet Sci. 2002 Aug;73(1):37-44
references.pmid: 12208105
references.citation: Vet Immunol Immunopathol. 2004 Aug;100(3-4):197-207
references.pmid: 15207457
references.citation: Can J Comp Med Vet Sci. 1967 Sep;31(9):226-33
references.pmid: 4227916
references.citation: Vet Rec. 1989 May 13;124(19):508-9
references.pmid: 2502878
references.citation: Vet Microbiol. 1994 Aug 1;41(3):213-9
references.pmid: 7975147
references.citation: FEMS Immunol Med Microbiol. 1995 Jun;11(3):171-80
references.pmid: 7581268
references.citation: Vet Microbiol. 1996 Oct;52(3-4):301-11
references.pmid: 8972056
references.citation: FEMS Microbiol Lett. 1997 Oct 15;155(2):203-7
references.pmid: 9351202
references.citation: Res Vet Sci. 2002 Jun;72(3):194-200
references.pmid: 12076113